JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - Leerink Partners has lowered its price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $21.00 from $22.00 while maintaining a Market Perform rating following the company’s fiscal third-quarter 2025 results. The stock, currently trading at $16.06, remains below analyst consensus targets ranging from $17 to $80. According to InvestingPro analysis, the company appears slightly undervalued based on its Fair Value metrics.
The biopharmaceutical company announced Thursday that it received a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT) for reaching the first of two prespecified enrollment targets for the Phase 1/2 trial of ARO-DM1. A second enrollment target, expected by year-end 2025, would trigger an additional $200 million milestone payment. InvestingPro data shows the company maintains a strong financial position with a current ratio of 5.15, indicating robust liquidity to fund its clinical programs.
Arrowhead completed enrollment in three Phase 3 trials—SHASTA-3, SHASTA-4, and MUIR-3—which could support plozasiran’s approval in severe hypertriglyceridemia, with data expected in mid-2026. The company also announced an asset purchase agreement between its majority-owned subsidiary Visirna and Sanofi (NASDAQ:SNY) for rights to plozasiran in China, worth $130 million upfront and up to $265 million in approval milestones.
The first patient was dosed in the Phase 3 YOSEMITE trial of zodasiran in homozygous familial hypercholesterolemia and in the Phase 1/2 trial of ARO-ALK7 in obesity. Additionally, the Phase 1/2 trial of ARO-INHBE is now enrolling patients in the multiple ascending dose combination arm with tirzepatide.
Leerink Partners cited updated financial disclosures as the reason for reducing its price target, while noting ongoing investor concerns about Sarepta potentially monetizing its equity investment or terminating the partnership, which has contributed to share volatility over the past two months. With a market capitalization of $2.2 billion and significant revenue growth potential, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports, available for over 1,400 US stocks.
In other recent news, Arrowhead Pharmaceuticals reported its financial results for the third quarter of fiscal 2025, revealing a net loss of $1.26 per share. This result was below analysts’ expectations, which had projected a loss of $0.86 per share. The company’s revenue also fell short of forecasts, coming in at $27.8 million compared to the anticipated $53.9 million. These financial figures have garnered attention from investors as they assess the company’s performance. The earnings miss underscores challenges Arrowhead Pharmaceuticals faces in meeting market expectations. Analysts and investors will likely be watching closely for any strategic changes or updates from the company in response to these results. Additionally, the financial community may look to analyst firms for their perspectives on Arrowhead’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.